Prognostic impact of N staging in 715 medullary thyroid cancer patients: Proposal for a revised staging system

Annals of Surgery

Volumn 257, Issue 2, 2013, Pages 323-329

  MacHens, Andreas ^a   Dralle, Henning ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

aggregate lymph node count; bone metastasis; extranodal growth; extrathyroidal extension; hepatic metastasis; mediastinal lymph node metastasis; medullary thyroid carcinoma; pulmonary metastasis

Indexed keywords

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER STAGING; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDULLARY THYROID CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; THYROID CANCER; THYROIDECTOMY;

ADULT; BONE NEOPLASMS; CARCINOMA, MEDULLARY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84872347982     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318268301d     Document Type: Article

References (35)

1. Edge SB, Byrd DR, Carducci MA, et al., eds. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009.
2. UICC. In: Sobin LH, Gospodarowicz MK, Wittekind CH, eds.TNM Classification of Malignant Tumours. 7th ed. Oxford, United Kingdom: Wiley-Blackwell; 2009.
3. Bergholm U, Adami HO, Telenius-Berg M, et al. Incidence of sporadic and familial medullary thyroid carcinoma in Sweden 1959 through 1981. A nationwide study in 126 patients. Swedish MCT Study Group. Acta Oncol. 1990;29:9-15.
4. Machens A, Hinze R, Thomusch O, et al. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26:22-28.
5. Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003;88:2070-2075.
6. Machens A, Holzhausen HJ, Dralle H. Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease? Surgery. 2006;139:28-32.
7. Lorenz K, Brauckhoff M, Behrmann C, et al. Selective arterial chemoem-bolization for hepatic metastases from medullary thyroid carcinoma. Surgery. 2005;138:986-993; discussion 993.
8. Fromigué J, De Baere T, Baudin E, et al. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:2496-2499.
9. Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185-4190.
10. Hyer SL, Vini L, A'Hern R, et al. Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol. 2000;26:686-690.
11. Moley JF, Wells SA, Dilley WG, et al. Reoperation for recurrent or persistent medullary thyroid cancer. Surgery. 1993;114:1090-1195; discussion 1095-1096.
12. Machens A, Holzhausen HJ, Lautenschläger C, et al. Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma. Cancer. 2003;98:712-719.
13. Ito Y, Miyauchi A, Yabuta T, et al. Alternative surgical strategies and favorable outcomes in patients with medullary thyroid carcinoma in Japan: experience of a single institution. World J Surg. 2009;33:58-66.
14. Leggett MD, Chen SL, Schneider PD, et al. Prognostic value of lymph node yield and metastatic lymph node ratio in medullary thyroid carcinoma. Ann Surg Oncol. 2008;15:2493-2499.
15. Machens A, Schneyer U, Holzhausen HJ, et al. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin En-docrinol Metab. 2005;90:2029-2034.
16. Dralle H, Damm I, Scheumann GFW, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today. 1994;24:112-121.
17. Dralle H. Lymph node dissection and medullary thyroid carcinoma. Br J Surg. 2002;89:1073-1075.
18. Dralle H. Malignant thyroid tumors [in German]. In: Garbe C, Albers P, Beckmann MW, et al., eds. Deutsche Krebsgesellschaft e. V. [Abbreviated interdisciplinary guidelines 2006. Recommendations for diagnosis and therapy of malignant diseases]. Munich/Vienna/New York: W. Zuckschwerdt Verlag; 2006.
19. World Health Organisation. International Histological Classification of Tumours. 2nd ed. Berlin, Germany: Springer; 1988.
20. DeLellis RA, Lloyd RV, Heitz PU, et al., eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Panigrahi B, Roman SA, Sosa JA. Medullary thyroid cancer: are practice patterns in the United States discordant from American Thyroid Association guidelines ? Ann Surg Oncol. 2010;17:1490-1498.
23. Kandil E, Gilson MM, Alabbas HH, et al. Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer. Ann Surg Oncol. 2011;18:1028-1034.
24. de Groot JW, Links TP, Sluiter WJ, et al. Locoregional control in patients with palpable medullary thyroid cancer: results of standardized compartment-oriented surgery. Head Neck. 2007;29:857-863.
25. Esik O, Szavcsur P, Szakáll S, Jr, et al. Angiography effectively supports the diagnosis of hepatic metastases in medullary thyroid carcinoma. Cancer. 2001;91:2084-2095.
26. Boostrom SY, Grant CS, Thompson GB, et al. Need for a revised staging consensus in medullary thyroid carcinoma. Arch Surg. 2009;144:663-669.
27. Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg. 1999;230:697-707.
28. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma. Recommendations for extent of node dissection. Ann Surg. 1999;229:880-888.
29. Kebebew E, Kikuchi S, Duh QY, et al. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg. 2000;135:895-901.
30. Yen TW, Shapiro SE, Gagel RF, et al. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery. 2003;134:890-899; discussion 899-901.
31. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2655-2663.
32. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19: 565-612.
33. Machens A, Gimm O, Ukkat J, et al. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer. 2000;88:1909-1915.
34. Bardet J, Campion L, Kraeber-Bodéré F, et al.; the GTC Study Group. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077-6084.
35. Giraudet AL, Al Ghulzan A, Aupérin A, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008;158:239-246.